RecruitingNot ApplicableNCT05299749
Real-time fMRI Neurofeedback in Patients With Schizophrenia and Auditory Hallucinations
Real-time fMRI Neurofeedback as a Tool to Mitigate Auditory Hallucinations in Patients With Schizophrenia - R33 Phase
Sponsor
Boston VA Research Institute, Inc.
Enrollment
104 participants
Start Date
Mar 1, 2022
Study Type
INTERVENTIONAL
Conditions
Summary
Neurofeedback intervention aimed to regulate the superior temporal gyrus (STG) activation and default mode network (DMN) connectivity as well as to reduce the auditory hallucinations (AH) schizophrenia patients with medication resistant AH.
Eligibility
Min Age: 18 YearsMax Age: 55 Years
Inclusion Criteria2
- patients diagnosed with SZ or schizoaffective disorder using DSM-5 criteria
- auditory hallucinations not responsive to pharmacology as determined by chart review and a clinical interview of SCID.
Exclusion Criteria6
- neurologic illness
- major head trauma
- electroconvulsive therapy
- alcohol or drug dependence
- alcohol or drug abuse within the past five years
- verbal IQ below 70
Interventions
OTHERstg-rt-fMRI-Neurofeeback
the patients will receive real-time feedback from the brain activity of the superior temporal gyrus
OTHERsham-rt-fMRI-Neurofeedback
the patients will receive real-time feedback from the brain activity of the somato-motor cortex
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05299749
Related Trials
Tolerability of MDMA in Schizophrenia
NCT057703751 location
Cromoglicate Adjunctive Therapy for Outpatients With Schizophrenia
NCT037940761 location
Cerebellar Stimulation and Cognitive Control
NCT032171101 location
A Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Participants With Schizophrenia
NCT0688278555 locations
Cerebellar Modulation of Cognition in Psychosis
NCT061077642 locations